PRECLINICAL STUDIES

NUBEQA IS AN ARI WITH A DISTINCT CHEMICAL STRUCTURE¹

ARI=androgen receptor inhibitor.

NUBEQA INHIBITS ANDROGEN RECEPTOR (AR) FUNCTION²

LOW BLOOD-BRAIN BARRIER PENETRATION IN PRECLINICAL MODELS

Two studies demonstrate low blood-brain barrier penetration with NUBEQA^5,6

In a preclinical mouse model

NUBEQA DEMONSTRATED MINIMAL PENETRATION ACROSS THE BLOOD-BRAIN BARRIER

3^%

BRAIN-TO-PLASMA RATIO

In a preclinical rat model

NUBEQA DEMONSTRATED LOW BLOOD-BRAIN BARRIER PENETRATION

8^%

BLOOD-BRAIN BARRIER PENETRATION

The penetration of NUBEQA across the human blood-brain barrier has not been studied

ARAMIS IS THE LARGEST PHASE III STUDY IN nmCRPC TO DATE^2,7,8

DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTER STUDY^2,9

Treatment continued until radiographic disease progression as assessed by conventional imaging (CT, MRI, ^99mTc bone scan) by blinded independent central review, discontinuation due to adverse reactions, or withdrawal of consent

*All patients received concurrent ADT (treatment with GnRH analog or previous bilateral orchiectomy).

^†Lymph nodes located below the aortic bifurcation as measured by the short axis.

CRPC=castration-resistant prostate cancer; PSADT=prostate-specific antigen doubling time; PSA=prostate-specific antigen; ECOG PS=Eastern Cooperative Oncology Group performance status;
ADT=androgen deprivation therapy; CT=computed tomography; MRI=magnetic resonance imaging; GnRH=gonadotropin-releasing hormone.

STUDY ENDPOINTS^2,9

PRECLINICAL STUDIES

Two studies demonstrate low blood-brain barrier penetration with NUBEQA5,6

The penetration of NUBEQA across the human blood-brain barrier has not been studied

ARAMIS IS THE LARGEST PHASE III STUDY IN nmCRPC TO DATE2,7,8

Two studies demonstrate low blood-brain barrier penetration with NUBEQA^5,6

ARAMIS IS THE LARGEST PHASE III STUDY IN nmCRPC TO DATE^2,7,8